Navigation Links
MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Date:8/12/2008

SAN DIEGO, Aug. 12 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, today announced the completion of two separate licensing agreements with the Memorial Sloan-Kettering Cancer Center's Sloan-Kettering Institute for Cancer Research (SKI).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080812/LATU515LOGO)

The first license agreement grants MabVax exclusive development and commercialization rights to multiple vaccines against recurrent cancer for six different types of cancer. MSKCC plans to initiate Phase I clinical trials in each of these types of cancer this year or early next year. Upon successful demonstration of immunogenicity and tolerability in the Phase I trials in sarcoma and small cell lung cancer, MabVax will initiate Phase II trials in these two cancer types. In addition to MabVax's efforts, MSKCC is planning to conduct Phase II trials with the licensed vaccines in ovarian and breast cancer. Pending successful outcomes, MabVax can assume responsibility for continued development and eventual commercialization of these vaccines.

The second license agreement grants MabVax exclusive rights to the use of the licensed vaccines and lymphocytes from successfully vaccinated clinical trial participants. MabVax plans to rescue antibodies from these patient samples to create a pipeline of fully human monoclonal antibody products against each of the vaccine targets expressed on the surface of the cancer cells. By rescuing antibodies from a selection of patients who generate a useful immune response, MabVax can select the optimal antibodies and develop them as either stand alone products or as combination products with the vaccines. MabVax has established a laboratory and office in the San Diego
'/>"/>

SOURCE MabVax Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... BCC Research report discusses the medical device technologies in terms ... and opportunities for different devices and regions. It includes forecasts ... the report focuses on technological trends in recent years in ... and Japan . Use ... device technologies market. - Analyze market structure, including segments and ...
(Date:9/18/2014)... , Sept. 18, 2014   Fruit Street Health ... an initial seed round of funding. ... led by a series of individual investors, the majority ... participated in the initial round are; Houston Cardiology ... Center Urologist Stacy Childs, Rapha Family Medicine Practice Owner ...
(Date:9/18/2014)...  ADM Tronics Unlimited, Inc. (OTCQB: ADMT) has ... corporate Advisory Board for business development. ... Medical School and Visiting Professor at the University ... degree in Electronics Engineering and his Ph.D. in ... After spending a year as a visiting researcher ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3
... KONG, Dec. 21, 2011 /PRNewswire-Asia-FirstCall/ -- Golden Meditech ... 801.HK; 910801.TW), China,s leading integrated healthcare enterprise, today announced ... shares in December 2011, equivalent to 0.49% of the ... of HK$0.84 per share.Mr. KAM Yuen, Chairman and Chief ...
...  BioDelivery Sciences International, Inc. (Nasdaq: ... study, BNX-102, assessing the pharmacokinetics of its ...  The results confirm the final formulation and ... the pivotal comparative pharmacokinetic study versus Suboxone.  ...
Cached Medicine Technology:Golden Meditech Repurchases Shares 2BioDelivery Sciences Announces Confirmation of Final Formulation of BEMA Buprenorphine/Naloxone Based on Positive BNX-102 Study 2BioDelivery Sciences Announces Confirmation of Final Formulation of BEMA Buprenorphine/Naloxone Based on Positive BNX-102 Study 3BioDelivery Sciences Announces Confirmation of Final Formulation of BEMA Buprenorphine/Naloxone Based on Positive BNX-102 Study 4
(Date:9/18/2014)... (PRWEB) September 18, 2014 It is that ... in health and wellness. Once again, Evensong Spa ... Week by offering three services at a special $50 rate ... managed by Marcus Hotels & Resorts , is the ... event encouraging Americans to embrace health and wellness by experiencing ...
(Date:9/18/2014)... Study after study has proven it true: exercise is ... Pennsylvania scientists suggests that exercise may have an added ... performed in a mouse model of melanoma, found that ... alone. , Joseph Libonati, an associate professor in ... of Innovative and Translational Nursing Research, was the senior ...
(Date:9/18/2014)... Lake City, UT (PRWEB) September 18, 2014 ... North America will be recognizing their shared fundraising impact ... on Thursday, Sept. 25. , The first-ever Dance Marathon ... more than $20 million projected to be raised by ... their community’s CMN Hospital. Donations generated through Dance Marathon ...
(Date:9/18/2014)... breeding grounds for microbes -- don,t worry, it,s a ... years, not all microbes are bad. Many active enzymes ... beneficial to humans as an important part of our ... , Candida albicans , an opportunistic yeast pathogen ... doesn,t damage our healthy personal ecosystem. However, when our ...
(Date:9/18/2014)... National Institutes of Health (NIH) recently awarded the first ... to the Los Angeles Biomedical Research Institute (LA BioMed) ... vaccine to protect patients from the healthcare-related infections, ... (MRSA). , The National Institute of Allergy and Infectious ... LA BioMed infectious disease specialists John E. Edwards, MD, ...
Breaking Medicine News(10 mins):Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... law stipulates that the Department of Veterans Affairs has ... have earned by virtue of their service to our ... of Vietnam Veterans of America (VVA). "What is ... inform veterans -- and the healthcare community -- of ...
... N.J., May 19 Quest Diagnostics Incorporated (NYSE: ... and services, announced today that it has commenced a cash ... amount (the "Tender Cap") of its 5.125% Senior Notes due ... The terms and conditions of the tender offer are described ...
... free swim classes for Gainesville children age 6 months ... Sebastian Ferrero Foundation is partnering with ... Center to provide over 300 local children the opportunity ... Swim for Safety event is part of an ongoing initiative coordinated ...
... by Prof. Nils Brose of the Max Planck Institute for ... of the European Union, to study the role of synaptic ... teams is headed by Prof. Kobi Rosenblum of the University ... awarded a grant of 600,000 Euro. The topic of the ...
... 19 A new Deloitte study profiling the ... Canada and Germany was released today at the ... findings of the report, available at ... comparative effectiveness has the potential to improve care ...
... Health Equipment business sold in two separate transactions-- ... additional working capital to fund DailyMed(TM) growthINDIANAPOLIS, May ... KAD ), a leading provider of home ... Arcadia HealthCare(SM) brand, today announced the sale of ...
Cached Medicine News:Health News:VA Needs Legislative Push to Inform Veterans of Health Issues Connected to Military Service 2Health News:Quest Diagnostics Commences Cash Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes 2Health News:Quest Diagnostics Commences Cash Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes 3Health News:Quest Diagnostics Commences Cash Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes 4Health News:Sebastian Ferrero Foundation Continues Support of Community Child Safety Programs 2Health News:Deloitte Comparative Effectiveness Study Evaluates Potential Savings Opportunities for U.S. Health Care System 2Health News:Deloitte Comparative Effectiveness Study Evaluates Potential Savings Opportunities for U.S. Health Care System 3Health News:Deloitte Comparative Effectiveness Study Evaluates Potential Savings Opportunities for U.S. Health Care System 4Health News:Deloitte Comparative Effectiveness Study Evaluates Potential Savings Opportunities for U.S. Health Care System 5Health News:Arcadia Resources Announces Sale of Non-Strategic Businesses 2Health News:Arcadia Resources Announces Sale of Non-Strategic Businesses 3Health News:Arcadia Resources Announces Sale of Non-Strategic Businesses 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: